DEVELOPMENT SAFETY UPDATE REPORT HALF DSUR č. 3

Title in English DEVELOPMENT SAFETY UPDATE REPORT HALF DSUR No. 3
Authors

DEMLOVÁ Regina BÁRTOVÁ Adéla

Year of publication 2023
MU Faculty or unit

Faculty of Medicine

Web HALF
Description A prospective clinical phase II evaluation study on a nationwide scale, the effectiveness and safety of discontinuation of tyrosine kinase inhibitors after a previous two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. The third periodic report on the HALF study evaluates the safety data received by the sponsor of the study during the period 6/16/2022 to 6/15/2023. Clinical evaluation is currently taking place in eight centers in the Czech Republic.

You are running an old browser version. We recommend updating your browser to its latest version.

More info